<DOC>
	<DOCNO>NCT00017485</DOCNO>
	<brief_summary>RATIONALE : Photodynamic therapy use light drug make cancer cell sensitive light kill tumor cell . Photosensitizing drug HPPH absorb cancer cell , expose light , become active kill cancer cell . PURPOSE : Phase I trial study effectiveness photodynamic therapy HPPH treat patient basal cell skin cancer .</brief_summary>
	<brief_title>Photodynamic Therapy Treating Patients With Basal Cell Skin Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety HPPH use photodynamic therapy patient basal cell skin cancer . - Determine drug dose , light dose , treatment interval combination produce excessive toxicity normal skin effect tumor response patient treat regimen . - Determine length time cutaneous photosensitivity patient treat regimen . - Determine plasma clearance rate HPPH patient . - Determine best combination treatment parameter phase II study . OUTLINE : This dose-escalation study . Patients receive HPPH IV day 1 . Patients undergo phototherapy day 2-3 . Cohorts 2-6 patient receive escalate dos HPPH phototherapy determine minimum erythemal dose ( MED ) . The MED define dose combination HPPH laser light precede least 1 patient experience grade 3 bad toxicity least 2 patient experience grade 1 bad toxicity . Patients follow daily 4 day , week 1 , month 1 , 3 , 6 , 12 , 24 . PROJECTED ACCRUAL : A total 4-25 patient accrue study .</detailed_description>
	<mesh_term>Carcinoma , Basal Cell</mesh_term>
	<mesh_term>Skin Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm nonmorpheaform basal cell skin cancer Primary disease OR Recurrent disease prior therapy ( e.g. , surgical excision , electrodesiccation , cryosurgery , radiotherapy ) At least 4 lesion , great 2 cm diameter great 5 mm depth No lesion locate eyelid , nose , ear , periauricular area , genitals , digit , lesion think deep and/or aggressive PATIENT CHARACTERISTICS : Age : Over 18 Performance status : Not specify Life expectancy : Not specify Hematopoietic : WBC least 2,000/mm^3 Platelet count least 120,000/mm^3 Hepatic : PT/PTT great 1.5 time upper limit normal ( ULN ) Bilirubin great 3.0 mg/dL Liver enzymes great 2 time ULN No impair hepatic function Renal : No impaired renal function Cardiovascular : No myocardial infarction within past 6 month Other : No porphyria No know hypersensitivity porphyrins No systemic lupus erythematosus No history positive antinuclear antibody No history degenerative disease retina No xeroderma pigmentosum No pancreatic disease Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 3 month since prior combination doxorubicin radiotherapy Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics See Chemotherapy Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>basal cell carcinoma skin</keyword>
	<keyword>recurrent skin cancer</keyword>
</DOC>